1 / 35

TRANSLATING GENOME WIDE ASSOCIATION STUDIES TO PREVENTION, DIAGNOSTICS, AND THERAPEUTICS

TRANSLATING GENOME WIDE ASSOCIATION STUDIES TO PREVENTION, DIAGNOSTICS, AND THERAPEUTICS. Alan E. Guttmacher, M.D. National Human Genome Research Institute May 1, 2007. GWAS Improved Health ?.

prisca
Download Presentation

TRANSLATING GENOME WIDE ASSOCIATION STUDIES TO PREVENTION, DIAGNOSTICS, AND THERAPEUTICS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TRANSLATING GENOME WIDE ASSOCIATION STUDIESTO PREVENTION, DIAGNOSTICS, AND THERAPEUTICS Alan E. Guttmacher, M.D. National Human Genome Research Institute May 1, 2007

  2. GWAS Improved Health? • Use of genetic information regarding common disease to individualize providers’ approach to patients and change patients’ behaviors in ways that lead to improved health (“Personalized Medicine”). • Use of genetic information regarding common disease to understand the biology of human disease to lead to improved diagnostic, therapeutic, and preventive approaches.

  3. GWAS vs. Study of “Single Gene” Disorders From large effects of single genes in rare, “single-gene” diseases to smaller effects of multiple genes in common, “complex” diseases

  4. Genomic Medicine 1. Heart disease (654,000 deaths in 2004) 2. Cancer (550,000) 3. Cerebrovascular diseases (150,000) 4. Chronic lower respiratory dis. (124,000) 5. Injury? (109,000) 6. Diabetes (73,000) 7. Alzheimer disease (66,000) 8. Pneumonia/Influenza (61,000) 9. Kidney disease (43,000) 10. Septicemia (33,000)

  5. Genomic Medicine • GWAS today, so new drug tomorrow? • No. There are many steps between GWAS and improved health...

  6. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  7. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  8. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  9. Identify gene(s)/gene product(s): Age-Related Macular Degeneration This and later articles show that three genes appear to account for approximately 74% of the attributable risk of AMD in older adults – and we did not even view this as a particularly “genetic” disorder…

  10. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  11. Develop Diagnostic Test • Test methodologies will vary • To develop the test requires investment of resources, supported either by public or private sector • A viable market is usually necessary if the test is to move from research use to clinical availability

  12. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  13. Analytical Validity, Clinical Validity and Clinical Utility • Analytical validity: The ability of a test to measure the characteristic that it was designed to measure. • Clinical validity: The ability of a test to distinguish affected and unaffected populations, including a determination of the probability of being affected. The clinical sensitivity, specificity, and predictive value of a test. • Clinical utility: The value of a test in diagnosing/ruling out a disease, in suggesting treatment or prevention strategies, and in evaluating risks and benefits associated with the test. (from CDC)

  14. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  15. Third Party Coverage • Without coverage for the lab component of the test, it will seldom be used • Coverage for the health professional time involved is also desirable, but MAY not be as necessary

  16. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  17. Define Function Scientists Identify 7 New Diabetes Genes By Nicholas Wade April 27, 2007, New York Times on-line “The importance of the new genes is that they point to previously unknown pathways involved in diabetes…. Several of the new variant genes make the pancreatic beta cells produce less insulin, Dr. Altshuler said. That suggests that diabetes may start as a disease of too little insulin production, even though patients turn up in the doctor’s office making too much insulin, to which their tissues have become resistant.”

  18. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  19. Identify Drug Target Once gene/protein function is understood, established strategies can be used to develop a new drug. But, support for development requires a market for the drug.

  20. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  21. Design Candidate Drug E.g., chemical genomics approach with quantitative high-throughput screen

  22. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  23. NIH’s Molecular Libraries Initiative Basic Biomedical Research Drug Development Phases Dedicated Chem-Biol Project Team formed Compound accepted into Clinical Development 1 yr 1 yr 1 yr ~ 3 yrs 1 yr 2 yrs ~3 yrs 1.5 yrs Indefinite Indefinite Lead Development, Optimization Ph I (Safety) Ph II (Dose finding, initial efficacy in patient pop.) Ph III (Efficacy and safety in large populations) Target identification Regulatory review Ph IV-V (Additional indications, Safety monitoring) Assay develop-ment Screening (HTS or otherwise) Hit-to-Probe

  24. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  25. Design Prevention Strategies “We believe it is premature at this time to consider genotyping individuals with various stages of AMD. Screening should consider (1) that genotyping of about 30 individuals with drusen/pigment changes would be required to identify 1 individual who is homozygous for the risk allele for both genes and (2) the observation that many but not all individuals with those genotypes will develop the disease. However, in the future, a risk profile that includes genetic and environmental factors, such as the one calculated herein, may ultimately lead to targeted screening and closer monitoring of individuals who are at higher risk of visual loss due to AMD progression. - Seddon, et al. JAMA. 2007;297:1793-1800.

  26. GWAS Prevention, Dx, and Rx GWAS Replicate/validate Identify gene(s)/gene product(s) Develop Dx test Define function Devise prevention/ non-drug therapeutic strategies Identify drug target Show analytic validity, clinical validity and utility Design candidate drug Clinical trials Validate via outcome studies Obtain third party payer coverage Obtain FDA approval

  27. Genomic Medicine But, even if we invent a better mouse trap… will the world beat a path to genomic medicine’s door?

  28. Genomic Medicine • Will require • Informed, interested providers • Informed, interested public

  29. A Pathway to Informed, Interested Providers URL: nchpeg.org

  30. A Pathway to an Informed, Interested Public The U.S. Surgeon General’s Family History Initiative URL: familyhistory.hhs.gov

  31. GWAS? • While many of today’s standard medical practices have never been proven to improve health or to make sense economically, we should use rigorous outcome and cost-benefit studies to decide which genomic medicine practices to utilize.

  32. Executive Summary • Will GWAS actually lead to prevention, diagnostics, and therapeutics for common disease?

  33. Executive Summary “Our age may be known to history as the age of genetic medicine, a time when many of the most feared illnesses were overcome.” - President Bush April 10, 2002

  34. Executive Summary “It is now conceivable that our children’s children will know the term cancer only as a constellation of stars.” - President Clinton June 26, 2000

More Related